CD8A and neoplasm: CD4.c16 and CD8.c11 both showed upregulation of CXCL13 in the MPR (Figure 1G), which was in line with the indispensable role of CXCL13 in identifying tumor-reactive CD8+ expanding T-cell clones in multiple cancer types (16, 53).